Kraft Heinz has been granted a patent for compositions and methods to modulate the mucosal immune system. The patent involves using a probiotic organism, Lactobacillus paracasei CBA L74, to ferment foods or as a pharmaceutical composition to treat gastrointestinal disorders in subjects. The L. paracasei CBA L74 cells used in the composition are either non-replicating or dead. GlobalData’s report on Kraft Heinz gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Kraft Heinz, Synthetic Resin containers was a key innovation area identified from patents. Kraft Heinz's grant share as of September 2023 was 64%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for using probiotic to treat gastrointestinal disorders
A recently granted patent (Publication Number: US11771102B2) describes a method for treating gastrointestinal disorders using a pharmaceutical composition containing a specific probiotic bacterium. The method involves identifying a subject with a gastrointestinal disorder and administering an effective amount of the pharmaceutical composition.
The pharmaceutical composition comprises a probiotic bacterium called Lactobacillus paracasei CBA L74, which is either dead or rendered incapable of cell division. The method can be used to treat various gastrointestinal disorders, including mucosal immune system deficits, food allergies, disorders associated with diarrhea, bacterial or viral infections, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, celiac disease, or necrotizing enterocolitis.
The method is particularly suitable for treating subjects with an immature immune system, such as human infants. In one embodiment, the pharmaceutical composition contains a culture supernatant of Lactobacillus paracasei CBA L74, which is free of intact cells. The composition can be administered in a unit dosage form ranging from about 1×102 cfu/g to about 1×1012 cfu/g dry weight of the probiotic bacterium.
Additionally, the composition may contain 0.01 to 1,000 mg per kg of the culture supernatant based on the weight of the subject.
This patent provides a method for effectively treating gastrointestinal disorders using a specific probiotic bacterium. By administering the pharmaceutical composition containing Lactobacillus paracasei CBA L74, the method aims to alleviate symptoms associated with various gastrointestinal disorders. The method's applicability to subjects with an immature immune system, such as human infants, suggests potential benefits for pediatric patients. The patent also highlights the importance of using a composition that is free of intact cells, ensuring the safety and efficacy of the treatment. The specified dosage forms and concentrations provide guidance for the administration of the pharmaceutical composition. Overall, this patent offers a promising approach to address gastrointestinal disorders and may have significant implications for the field of gastroenterology.